Characteristics of vascularization of muliformis glioblastoma of the brain hemisphere with the use of intervention neuroradiological methods
EANS Academy. Bobryk I. 09/25/19; 275864; EP03026
Ivan Bobryk
Ivan Bobryk

Access to this content is reserved for EANS members and attendees of this event. Click here to become an EANS member and gain your access to the full content of the EANS Academy


Abstract
Discussion Forum (0)
Rate & Comment (0)
Abstract: The aim: to show the effectiveness of Digital Subtraction Angiography and Superselective Angiography in patients with GBM. To describe peculiarities of vascular architecture and hemodinamic of tumor and to study its pathomofology in certain clinical cases. Identify the possibility of conducting superselective chemotherapy with temozolamide.
Materials and methods: We selected 22 patients with GBM of brain hemisphere for this research. Patient underwent Digital Subtraction Angiography, Computer Tumography and Magnetic Resonance Imaging. In 2 cases we examined Superselective Cerebral Angiography of tumor locus, the description of morfological characteriscits in comprative grups was made. An immunohistochemical study was performed using monoclonal antibodies (MATs) to VEGF, CD31, Ki-67, GFAP.
Results: Performing DSA in patients with GBM we obtained a certain information about vascular architecture and hemodinamics of tumor. High sensitivity of the method was shown for this type of pathology. Morfological peculiarities of comparetive grups was collected. Detected expression of VEGF in sensitive and non-sensitive samples to temozolamide.
Conclusion: The information of DSA and Superselective Cerebral Angiography in patients with GBM gives an opportunity to estimate the vascularity of the tumor and opens new perspectives of using interventional neuroradiological methods in this type of pathology. In most samples of temozolamide sensitive, the expression of VEGF was high.
Key words: GMB (Glioblastoma multiformis), DSA (Digital Subtraction Angiography), Superselective Cerebral Angiography, Vascular malformation, Drain veins, tumor artheries, tumor veins, VEGF (Vascular endothelial growth factor),TMZ (Temozolomide).
Abstract: The aim: to show the effectiveness of Digital Subtraction Angiography and Superselective Angiography in patients with GBM. To describe peculiarities of vascular architecture and hemodinamic of tumor and to study its pathomofology in certain clinical cases. Identify the possibility of conducting superselective chemotherapy with temozolamide.
Materials and methods: We selected 22 patients with GBM of brain hemisphere for this research. Patient underwent Digital Subtraction Angiography, Computer Tumography and Magnetic Resonance Imaging. In 2 cases we examined Superselective Cerebral Angiography of tumor locus, the description of morfological characteriscits in comprative grups was made. An immunohistochemical study was performed using monoclonal antibodies (MATs) to VEGF, CD31, Ki-67, GFAP.
Results: Performing DSA in patients with GBM we obtained a certain information about vascular architecture and hemodinamics of tumor. High sensitivity of the method was shown for this type of pathology. Morfological peculiarities of comparetive grups was collected. Detected expression of VEGF in sensitive and non-sensitive samples to temozolamide.
Conclusion: The information of DSA and Superselective Cerebral Angiography in patients with GBM gives an opportunity to estimate the vascularity of the tumor and opens new perspectives of using interventional neuroradiological methods in this type of pathology. In most samples of temozolamide sensitive, the expression of VEGF was high.
Key words: GMB (Glioblastoma multiformis), DSA (Digital Subtraction Angiography), Superselective Cerebral Angiography, Vascular malformation, Drain veins, tumor artheries, tumor veins, VEGF (Vascular endothelial growth factor),TMZ (Temozolomide).
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies